NP_579856.1
[Other Products]
NCBI GenBank Nucleotide #
|
[Other Products]
UniProt Primary Accession #
|
[Other Products]
UniProt Related Accession #
Molecular Weight
93,949 Da
NCBI Official Full Name
potassium voltage-gated channel subfamily KQT member 2
NCBI Official Synonym Full Names
potassium voltage-gated channel, KQT-like subfamily, member 2
NCBI Protein Information
potassium voltage-gated channel subfamily KQT member 2; KQT-like 2; potassium channel subunit alpha KvLQT2; voltage-gated potassium channel subunit Kv7.2; potassium voltage-gated channel, subfamily Q, member 2
UniProt Protein Name
Potassium voltage-gated channel subfamily KQT member 2
UniProt Synonym Protein Names
KQT-like 2; Potassium channel subunit alpha KvLQT2; Voltage-gated potassium channel subunit Kv7.2
UniProt Entry Name
KCNQ2_RAT
NCBI Summary for KCNQ2
potassium channel involved in sympathetic neuronal excitability [RGD, Feb 2006]
UniProt Comments for KCNQ2
Kv7.2: Probably important in the regulation of neuronal excitability. Associates with KCNQ3 to form a potassium channel with essentially identical properties to the channel underlying the native M-current, a slowly activating and deactivating potassium conductance which plays a critical role in determining the subthreshold electrical excitability of neurons as well as the responsiveness to synaptic inputs. KCNQ2/KCNQ3 current is blocked by linopirdine and XE991, and activated by the anticonvulsant retigabine. Muscarinic agonist oxotremorine-M strongly suppress KCNQ2/KCNQ3 current in cells in which cloned KCNQ2/KCNQ3 channels were coexpressed with M1 muscarinic receptors. Defects in KCNQ2 are the cause of benign familial neonatal seizures type 1 (BFNS1). A disorder characterized by clusters of seizures occurring in the first days of life. Most patients have spontaneous remission by 12 months of age and show normal psychomotor development. Some rare cases manifest an atypical severe phenotype associated with epileptic encephalopathy and psychomotor retardation. The disorder is distinguished from benign familial infantile seizures by an earlier age at onset. In some patients, neonatal convulsions are followed later in life by myokymia, a benign condition characterized by spontaneous involuntary contractions of skeletal muscles fiber groups that can be observed as vermiform movement of the overlying skin. Electromyography typically shows continuous motor unit activity with spontaneous oligo- and multiplet- discharges of high intraburst frequency (myokymic discharges). Some patients may have isolated myokymia. Defects in KCNQ2 are the cause of epileptic encephalopathy early infantile type 7 (EIEE7). EIEE7 is an autosomal dominant seizure disorder characterized by infantile onset of refractory seizures with resultant delayed neurologic development and persistent neurologic abnormalities. Belongs to the potassium channel family. KQT (TC 1.A.1.15) subfamily. Kv7.2/KCNQ2 sub-subfamily. 6 isoforms of the human protein are produced by alternative splicing.
Protein type: Membrane protein, multi-pass; Channel, potassium; Membrane protein, integral
Cellular Component: voltage-gated potassium channel complex; protein complex; plasma membrane; integral to membrane
Molecular Function: protein binding; voltage-gated potassium channel activity; delayed rectifier potassium channel activity; protein N-terminus binding; ankyrin binding
Biological Process: membrane hyperpolarization; transmission of nerve impulse
Research Articles on KCNQ2
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice. It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Pathways associated with KCNQ2 elisa kit
Diseases associated with KCNQ2 elisa kit
Organs/Tissues associated with KCNQ2 elisa kit
|